Compositions and methods for selective phagocytosis of human cancer cells
AssigneeThe Trustees of the University of Pennsylvania
InventorsDennis E. Discher, Kyle R. Spinler, Cory Alvey
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions and methods that provide novel therapies in cancer. The invention includes a phagocytic cell modified with a repressor of signal regulatory protein-alpha (SIRPα) and bound to a targeting antibody to enhance phagocytic activity of the phagocytic cell toward tumor tissue. Methods of enhancing phagocytic activity and treating a tumor are also included.
Claims36
A composition comprising a modified macrophage comprising a repressor of signal regulatory protein-alpha (SIRPα), and a pharmaceutically acceptable carrier;
- wherein the repressor of SIRPα is selected from the group consisting of a SE7C2 antibody and a P84 antibody;
- and
- wherein the macrophage is bound to a MA5-15131 targeting antibody and possesses phagocytic activity against tumor tissue.
A composition comprising a signal regulatory protein-alpha (SIRPα) repressed bone marrow cell bound to a targeting antibody;
- and a pharmaceutically acceptable carrier;
- wherein the repressor of SIRPα is selected from the group consisting of a SE7C2 antibody and a P84 antibody;
- and
- wherein the bone marrow cell is bound to a MA5-15131 targeting antibody and possesses phagocytic activity against tumor tissue.
Dependencies are inferred from the claim text.